Maria Kataki
Neurology · Columbus, OHNPI 1144304064
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Eisai Inc. accounts for 85.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in OH, where the typical reported total is $970.
Across 2 payments — averaging $73.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$125
- SK Life Science, Inc.$22
Across 25 payments — averaging $25,028 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$277K
- Novartis$234K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$68K
- Avanir Pharmaceuticals, Inc.$47K
What the payments were for
- Food & beverage$147100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 1 | $125 |
| SK Life Science, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$125
How this compares
$147 in reported general payments places this provider in the 25th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 202 | $15,652 |
| Memantine Hcl | 192 | $6,978 |
| Donepezil Hcl | 130 | $2,041 |
| Divalproex Sodium | 45 | $1,861 |
| Quetiapine Fumarate | 90 | $1,593 |
| Mirtazapine | 23 | $789 |
| Escitalopram Oxalate | 75 | $558 |
| Duloxetine Hcl | 20 | $488 |
| Sertraline Hcl | 74 | $352 |
| Citalopram HbrCitalopram Hydrobromide | 47 | $280 |
| Risperidone | 24 | $233 |
| Trazodone Hcl | 35 | $226 |
| Buspirone Hcl | 16 | $119 |
| Lorazepam | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Allison JordanColumbus$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.